Anticoagulation module 3: Anticoagulant therapy

Released 27 October 2021     Expires: 27 October 2023      Programme: Anticoagulation 1.5 CPD/CME credits

Sponsorship Statement:

This latest 2021 revision and earlier revisions of the anticoagulation modular programme have been funded by educational grants from Bayer. Bayer had no role in the writing of the modules and had no editorial control over the content.

The programme was originally supported by an educational grant from Bristol Myers Squibb (BMS) and Pfizer. BMS and Pfizer had no role in the writing of the modules and had no editorial control over the content.

Designed to give healthcare professionals a clear understanding of the mechanism of coagulation and how this relates to the development of arterial and venous thrombosis. It is one of several modules in our anticoagulation programme.

Module first published: 10 April 2013
First revision: 01 April 2016
Second revision: 10 January 2019
Third revision: 27th October 2021

Learning objectives

Upon completing this module, participants should be better able to:

  • Understand key aspects of the coagulation pathway
  • Discuss the action of heparin, low molecular weight heparin, fondaparinux and vitamin K antagonists such as warfarin
  • Recognise the mode of action of direct oral anticoagulants
  • Appreciate the uses of anticoagulants in acute coronary syndromes and atrial fibrillation
  • Prepare for the consequences of mis-managed anticoagulation, including haemorrhage.


Dr Andrew Blann, Consultant Clinical Scientist, City Hospital, Birmingham
First revision (2016) by Dr Matthew Rogers, Locum Consultant Haematologist, Royal Surrey County Hospital, Guildford
Second revision (2019) by Dr Zara Sayar, Haematology Consultant, Whittington Health NHS Trust, London, and University College Hospital, London
Third revision (2021) by Dr Prabal Mittal, Haematology Clinical Research Fellow, University College London Hospitals NHS Foundation Trust, in association with Dr Zara Sayar


1.5 CPD/CME credits, 1.5 hours
BJC Learning has assigned one and a half hours of CPD/CME credit to this module

Endorsed by:

You need to login to take this module

You need to be a registered member to view this page. It's quick, free and offers you a host of other benefits, including the facility to print and download articles and supplements, access our archived issues and receive email updates when new issues and other content are online.

210 thoughts on “Anticoagulation module 3: Anticoagulant therapy”

All rights reserved. No part of this programme may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers, Medinews (Cardiology) Limited.

It shall not, by way of trade or otherwise, be lent, re-sold, hired or otherwise circulated without the publisher’s prior consent.

Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs becomes necessary. The editors/authors/contributors and the publishers have taken care to ensure that the information given in this text is accurate and up to date. Readers are strongly advised to confirm that the information, especially with regard to drug usage, complies with the latest legislation and standards of practice.

Healthcare professionals should consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews (Cardiology) Limited cannot accept responsibility for any errors in prescribing which may occur.